). Because of the observed variation in ciprofloxacin half-life in our anephric volunteers, we also recommend that a schedule of administration every 12 h be maintained, even for patients without urine output.
Ciprofloxacin is a new quinoline carboxylic acid with a broad range of activity (5) . Since this antibiotic may be used intravenously, it may have a place in the therapy of serious nosocomial infections.
We previously studied the pharmacokinetic behavior of 200 mng of ciprofloxacin administered intravenously to normal volunteers (3) . We found that renal clearance accounted for 67 ± 11% (mean ± standard deviation) of the total serum clearance. Consequently, one would expect that seriously ill patients, who may have renal dysfunction, would have an impaired clearance of ciprofloxacin compared with that of normal volunteers. We therefore undertook a study of the pharmacokinetic behavior of 200 mg of ciprofloxacin administered intravenously to patients with various degrees of renal functional impairment.
MATERIALS AND METHODS
Selection of patients. Thirty-two patients with various degrees of renal function were studied. All volunteers selected for study had given written informed consent according to institutional guidelines. They were divided into four groups on the basis of renal function. Patients in group 1 had measured creatinine clearances greater than 6 liters/h per 1.73 M2. Group 1 volunteers were a subset (8 of 12) of previously reported normal volunteers receiving 200 mg of ciprofloxacin intravenously (4) . Group 2 subjects had creatinine clearances greater than or equal to 3.6 and less than 6.0 liters/h per 1.73 M2. Group Specimen collection and handling. Blood was obtained for ciprofloxacin assay prior to drug administration. Samples were also obtained (in all instances from the arm contralateral to drug administration) at the end of infusion for all groups. For group 1 subjects, samples were also taken at 0.25, 0.33, 0.42, 0.67, 0.92, 1.17, 1.67, 2.17, 3.17, 4.17, 6.17, 8.17, 12.17, and 24.17 h after the infusion was begun. For patients in groups 2 through 4, samples were also obtained at 0.75, 1, 1.25, 1.5, 2, 2.5, 3.5, 4.5, 6.5, 8.5, 12.5, 16.5, 24.5, 36.5, and 48.5 h after the infusion was begun. Blood was allowed to clot, and serum was separated and promptly frozen at -20°C or below until the time of assay.
Urine was obtained for ciprofloxacin assay prior to drug administration and quantitatively at 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 h after the initiation of drug administration for all volunteers. Those in groups 2 through 4 also had urine collectd at 48 to 72 h. Urine volumes were measured, and samples were frozen at -20°C or below until the time of assay.
Drug assay. Ciprofloxacin in serum and urine was measured by high-pressure liquid chromatography by a variant of the assay of Gau et al. (6) . The serum assay involved the use of protein precipitation, reverse-phase high-pressure liquid chromatography and fluorometric detection. The urine assay involved the use of sample dilution followed by direct injection. Quinine was used as the internal standard. A Waters Associates C-18 micro-Bondapak reverse-phase column was used. The mobile phase consisted of 27% methanol, 0.8% tetrahydrofuran, and 0.67 M phosphate buffer (pH 
3.0)
. A flow rate of 1.3 ml/min was used. The column was heated to 50°C. Ciprofloxacin peaks in urine chromatograms were checked for purity (to rule out assay interference from metabolites) by full-spectrum UV scanning with an HP1040 Diode Array high-pressure liquid chromatography detector (Hewlett-Packard Co.).
The standard curves were linear between 0.01 and 1 ,ug/ml for serum and between 0.025 and 1.5 ,ug/ml for urine. Dilutions at these ranges were prepared by using blank serum for the serum assay and phosphate buffer for the urine assay. The sensitivity of the assays was at least 0.01 ,ug/ml. Percent coefficients of variation between days for serum for serum were 5.5% at 0.091 ,ug/ml and 4.3% at 0.859 ,g/ml.
For the urine assay, percent coefficients of variation were 4.2% at 0.046 jig/ml and 5.3% at 0.455 ,ug/ml. tients have no renal clearance, the renal clearance-creatinine clearance regression was constrained to a zero intercept (i.e., the regression line was forced through zero). RESULTS Demographic information for the 32 patients studied is summarized in Table 1 .
The mean concentration-time profiles for serum clearance for the four groups of patients are displayed in Fig. 1 The regression relationship between normalized serum clearance and normalized creatinine clearance is in Fig. 2 . As can be seen, there is a rather good correlation between serum clearance and creatinine clearance (r = 0.697, P < 0.001). This is particularly impressive when one considers that only 50 to 70% of the drug is renally cleared, even in normal individuals, and that much of the renal clearance must be by active secretion (3).
The regression relationship between normalized renal clearance and creatinine clearance is displayed in Fig. 3 can be seen, the line has been forced through zero. The slope of the line is very similar to that seen for the serum clearance relationship. An even stronger correlation is noted between renal clearance and creatinine clearance (r = 0.845, P < 0.001). As the slope of this line attests, the renal clearance is approximately twice the creatinine clearance and is probably explained by substantial active tubular secretion. Much of the unexplained variance in these regressions is probably due to differences in active secretion into the urine.
A less strong correlation between 1B and normalized creatinine clearance was noted. The correlation coefficient for this relationship was r = 0.658 (P < 0.001). The greater inherent variability of the elimination rate constant is reflected in the scatter observed in the half-life (Fig. 4) . The hyperbola in this figure is derived from the 1-creatinine clearance regression relationship.
No correlation was detected between normalized nonrenal clearance and creatinine clearance. The best-fit line had a correlation coefficient of only 0.201. The slope of this line (-0.32) was not significantly different from zero, and the intercept (13.97) was very similar to the intercept obtained in the serum clearance-creatinine clearance regression relationship (13.23).
DISCUSSION
Ciprofloxacin is a new quinoline carboxylic acid whose clearance pathways include renal clearance by glomerular filtration and active tubular secretion, as well as significant metabolic clearance with the production of at least four metabolites (a metabolite in which the piperazine ring on position 7 is opened with the loss of an ethyl function, a sulfated metabolite, an oxo-compound, and a formyl metabolite [A. Heyd, personal communication]).
Hospitalized and elderly patients frequently have impaired renal function. Because of multiple clearance pathways for ciprofloxacin, the effect of declining renal function on overall serum clearance is difficult to predict. Because both drug efficacy and toxicity may be related to concentrations in serum, an accurate idea of the impact of altered renal function on drug clearance is important.
Because ciprofloxacin possesses multiple pathways of clearance, anephric patients still had a total serum clearance averaging 15.4 liters/h per 1.73 m2 and a lowest observed value of 11 liters/h per 1.73 m2 in the eight patients we studied. This is in contrast to the mean value of 26.8 liters/h per 1.73 m2, with a minimum observed value of 21.4 liters/h per 1.73 m2 in the normal volunteers. Consequently, it is apparent that major dose alteration is unnecessary for ciprofloxacin and should be limited to a maximum 50% dose reduction, which should be initiated at creatinine clearances between 1.2 and 1.8 liters/h per 1.73 m2 (20 to 30 ml/min per 1.73 mi2). maintained as the minimum average concentration in serum for the patients receiving half the normal daily dose (i.e., those with creatinine clearances less than 1.2 liters/h per 1.73 mi2) will be similar to the mean concentration in serum seen for normals receiving the full dose.
It is also clear that this dose adjustment should be done by reducing the dose and maintaining the normal schedule (administration every 12 h). In our group of eight anephric patients, although there was relatively little variation in serum clearance, there was a very wide variation in observed terminal elimination half-life, with a minimum of 3.9 h and a maximum of 13.5 h. Clearly, if one is dealing with a patient for whom the half-life is 10 to 12 h, administration of a normal dose (200 mg) every 24 h may be appropriate. However, if the half-life is 4 to 6 h, administration of a normal dose every 24 h would result in long periods at potentially subtherapeutic concentrations. Consequently, because of the unpredictability of half-life even for anephric patients, the safety of the patients would best be served by altering the dose size and maintaining the dosing interval.
The effect of renal dysfunction on oral ciprofloxacin Consequently, the validity of the observed halflives in both instances is unknown. Since ciprofloxacin is not extensively protein bound (A. Heyd, personal communication), the variability of the half-life noted is most probably due to differences in hepatic clearance among individuals as influenced by the underlying disease state of the patient. In summary, the regression relationships developed between normalized creatinine clearance and serum clearance and renal clearance for ciprofloxacin explain much of the variance which we observed. That remaining is probably due mainly to differences among individuals in active urinary secretion and metabolism. The presence of a large, relatively invariant, metabolic clearance pathway for ciprofloxacin ensures that even anephric patients will still have a substantial serum clearance. Because of this, reductions in the daily dose for patients with declining renal function should be limited to a maximum of 50% initiated between 1.2 and 1.8 liters/h per 1.73 m2 (20 to 30 ml/min per 1.73 m2) and, because the variation in half-lives is large, the maximum dosing interval for patients with serious infections should be 12 h.
Readers wishing to examine the model-dependent pharmacokinetic parameter values may obtain them by contacting the corresponding author.
